What is Singulair (montelukast) classified as?

Singulair, or montelukast, is classified as a leukotriene receptor antagonist. This means it works by blocking the action of leukotrienes, which are substances in the body that contribute to inflammation, bronchoconstriction, and mucus production in the airways. By inhibiting these leukotriene receptors, montelukast helps to reduce inflammation and relax the airways, making it particularly useful in managing chronic asthma and allergic rhinitis.

Leukotrienes play a significant role in the pathophysiology of asthma symptoms, including wheezing and difficulty breathing. Therefore, montelukast can be an effective preventative treatment for asthma attacks, particularly in individuals who have difficulty using inhalers or prefer an oral medication.

In contrast, short-acting bronchodilators and long-acting bronchodilators are classes of medications that directly relax bronchial smooth muscle to relieve symptoms of asthma or COPD but do not affect leukotriene pathways. Inhaled corticosteroids are anti-inflammatory medications typically used to control asthma and other inflammatory conditions, primarily by reducing airway inflammation rather than blocking leukotriene effects specifically.